There are limited treatment options for patients with advanced/metastatic, triple-negative breast cancer because commonly used treatments in other breast cancer segments (i.e., hormonal therapies and HER2-targeted therapies) are ineffective in this disease subset. Hence, a high unmet need exists for efficacious targeted therapies for this patient population. Several novel therapies are in development for advanced/metastatic, triple-negative breast cancer; however, historically, it has been difficult for agents to improve outcomes for this hard-to-treat population. Our content examines key drivers of prescribing in this indication and analyses of significant commercial opportunities.
Breast Cancer | Landscape & Forecast | Disease Landscape & Forecast
Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4
Breast Cancer | Disease Landscape and Forecast | G7 | 2019
Characterized by high incidence and long treatment durations, the breast cancer market represents a g...
Breast Cancer | Unmet Need | Detailed, Expanded Analysis: Advanced/Metastatic Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a patient population with high unmet need given the poor outcomes associated with current treatment...
Breast Cancer | Access & Reimbursement | Detailed, Expanded Analysis - Optimizing Market Access Amid an Evolving Landscape for HR+/HER2- Therapies (EU)
MARKET OUTLOOK The lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novar...